Stocks Health care BNTC
NASDAQ · Health careBenitec Biopharma Inc. (BNTC)
It posted a net loss of $45.5M. In fiscal 2026 capital spending exceeded operating cash flow by $16.6M. At June 30, 2026 it held $180M in cash. Its latest periodic report to the SEC is the annual report (10-K) filed on September 14, 2026.
Key facts about Benitec Biopharma Inc.
- Net worth
- Benitec Biopharma Inc. has a market value (market cap) of $320.2M at the latest share price, and shareholders' equity of $177M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0 (-100.0% year on year), with a net loss of $21.8M.
- Cash flow
- In fiscal 2026 operations used $16.5M of cash.
- Latest report
- The latest periodic report (annual report, 10-K) was filed with the SEC on September 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Benitec Biopharma Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Benitec Biopharma Inc. does
Benitec Biopharma Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BNTC.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | n/a | -$45.5M | -$0.98 | -$16.6M |
| 2025 | n/a | -$37.9M | -$1.05 | -$23.6M |
| 2024 | $0 | -$21.8M | -$1.22 | -$19.6M |
| 2023 | $75K | -$19.6M | -$3.13 | -$18M |
| 2022 | $73K | -$18.2M | -$8.39 | -$15.9M |
| 2021 | $59K | -$13.9M | -$12.15 | -$13.1M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Benitec Biopharma Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 28, 2026
- October 20, 2026Additional proxy material DEFA14A
- October 20, 2026Proxy statement DEF 14A
- October 5, 2026
- September 30, 2026Auditor change 8-K
- September 24, 2026Auditor change 8-K
- September 14, 2026
- September 14, 2026
- September 14, 2026
- May 29, 2026
Insider trades
What the people running Benitec Biopharma Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 29, 2026 | Buchi J KevinDirector | Gave as a gift | 51,813 | - |
| December 29, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 65,800 | $884.4K |
| December 29, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 11,587 | $155.7K |
| December 26, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 14,320 | $187.6K |
| December 26, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 2,516 | $33K |
| December 23, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 42,600 | $547.4K |
| December 23, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 7,400 | $95.1K |
| December 22, 2025 | Suvretta Capital Management, LLCDirector, 10% owner | Boughtindirect | 16,650 | $201.1K |
Who owns BNTC
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Suvretta Capital Management, LLC13D, may seek influence with 3 related filers | 44.1% | November 10, 2025 |
| Janus Henderson Group PLC13G, passive with 1 related filers | 9.99% | December 8, 2025 |
| RA Capital Management, L.P.13G, passive with 3 related filers | 5.5% | December 3, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 87 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Montanova Capital, LLC | 11,548,351 | 0 |
| Nantahala Capital Management, LLC | 2,976,742 | +1,538,371 |
| Jupiter Topco LLC | 2,478,547 | new |
| Franklin Resources Inc | 2,412,888 | +34,729 |
| Adage Capital Partners GP, L.L.C. | 2,120,672 | 0 |
| RA Capital Management, L.P. | 1,850,000 | 0 |
| BlackRock, Inc. | 1,407,138 | +221,397 |
| Simplify Asset Management Inc. | 1,005,557 | +443,315 |
| Vanguard Capital Management LLC | 954,533 | +22,977 |
| Infinitum Asset Management, LLC | 923,006 | 0 |
| Millennium Management LLC | 921,299 | +269,235 |
| Alyeska Investment Group, L.P. | 750,000 | 0 |
| Silverarc Capital Management, LLC | 679,826 | -37,899 |
| Balyasny Asset Management L.P. | 650,503 | -3,332 |
| Geode Capital Management, LLC | 611,736 | +87,632 |
| Ameriprise Financial Inc | 401,245 | -7,525 |
| State Street Corp | 377,973 | +39,724 |
| MYDA Advisors LLC | 250,000 | +25,000 |
| Schonfeld Strategic Advisors LLC | 235,357 | +82,178 |
| AWM Investment Company, Inc. | 187,977 | 0 |
Insiders
2 insiders reported holding 1,900,253 shares in total, about $17.7M at the last price.
| Holder | Shares |
|---|---|
| Suvretta Capital Management, LLCDirector, 10% owner | 1,848,1561,848,156 held indirectly |
| Buchi J KevinDirector | 52,097 |
Questions about BNTC
What does Benitec Biopharma Inc. do?
Benitec Biopharma Inc. is a company in the Health care sector, listed on NASDAQ as BNTC. Its shares trade on NASDAQ under the ticker BNTC.
What is Benitec Biopharma Inc.'s net worth?
Benitec Biopharma Inc. has a market value (market cap) of $320.2M at the latest share price, and shareholders' equity of $177M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Benitec Biopharma Inc. profitable?
No. In fiscal 2026 it reported a net loss of $45.5M.
When did Benitec Biopharma Inc. last report?
Its most recent periodic report is the annual report (10-K) filed on September 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 28, 2026.
When is Benitec Biopharma Inc.'s next earnings report?
Benitec Biopharma Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BNTC with
Follow BNTC
Get an email when Benitec Biopharma Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Benitec Biopharma Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.